Co-Authors
This is a "connection" page, showing publications co-authored by SANKAR NAVANEETHAN and LUCILE GREGG.
Connection Strength
8.870
-
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD. J Am Soc Nephrol. 2025 Jan 01; 36(1):87-98.
Score: 0.968
-
Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD. Clin J Am Soc Nephrol. 2023 11 01; 18(11):1479-1482.
Score: 0.897
-
Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant. 2023 05 31; 38(6):1355-1365.
Score: 0.888
-
Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Am J Nephrol. 2023; 54(3-4):126-135.
Score: 0.886
-
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. Am J Kidney Dis. 2023 07; 82(1):53-62.e1.
Score: 0.867
-
Considerations in the Study of Body Mass Index Variability. J Am Soc Nephrol. 2021 10; 32(10):2395-2397.
Score: 0.791
-
Are All SGLT2 Inhibitors Created Equal? Clin J Am Soc Nephrol. 2021 09; 16(9):1309-1311.
Score: 0.787
-
Early eGFR decline after SGLT2i initiation: knowns and unknowns. Kidney Int. 2021 03; 99(3):548-550.
Score: 0.760
-
Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Res Care. 2021 07; 9(1).
Score: 0.389
-
Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study. Cardiorenal Med. 2024; 14(1):34-44.
Score: 0.231
-
Natriuretic peptides, extracellular volume, and subclinical cardiovascular changes in chronic kidney disease stages 1-3: a pilot study. J Investig Med. 2022 Jul 19.
Score: 0.209
-
Revisiting diuretic choice in chronic kidney disease. Curr Opin Nephrol Hypertens. 2022 09 01; 31(5):406-413.
Score: 0.209
-
Effects of the 2021 CKD-EPI Creatinine eGFR Equation among a National US Veteran Cohort. Clin J Am Soc Nephrol. 2022 02; 17(2):283-285.
Score: 0.200
-
Incidence and predictors of non-alcoholic fatty liver disease among patients with chronic kidney disease. Nephrol Dial Transplant. 2021 07 23; 36(8):1546-1548.
Score: 0.195
-
Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. Am J Kidney Dis. 2021 11; 78(5):700-708.e1.
Score: 0.192
-
Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5. Hypertension. 2021 03 03; 77(3):948-959.
Score: 0.188
-
Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators. Kidney Med. 2024 Jun; 6(6):100830.
Score: 0.059
-
Improving chronic kidney disease detection and treatment in the United States: the chronic kidney disease cascade of care (C3) study protocol. BMC Nephrol. 2022 10 12; 23(1):331.
Score: 0.053
-
Heart failure-type symptom scores in chronic kidney disease: The importance of body mass index. Int J Obes (Lond). 2022 10; 46(10):1910-1917.
Score: 0.053
-
Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2022 06; 248:160-162.
Score: 0.050